Trial Profile
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Tisotumab-vedotin (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms innovaTV 204
- Sponsors Genmab; Seagen
- 01 Sep 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record (2 Aug 2022).
- 23 Jun 2022 Status changed from active, no longer recruiting to completed.
- 20 Sep 2021 According to a Seagen, Genmab AS media release, based on the data from this trial, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK,for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is approved under the FDA Accelerated Approval Program based on tumor response and the durability of the response.